Tudor Investment Corp
FDMT icon

Tudor Investment Corp’s 4D Molecular Therapeutics FDMT Stock Holding History

Tudor Investment Corp’s Portfolio FDMT Stock Details FDMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-31,815
Closed -$239K – 3832
2025
Q4 		$239K Buy
31,815
+6,048
+23% +$61.4K ﹤0.01% 3186
2025
Q3 		$224K Buy
25,767
+388
+2% +$2.32K ﹤0.01% 3149
2025
Q2 		$94.2K Sell
25,379
-20
-0.1% -$70 ﹤0.01% 3154
2025
Q1 		$82K Sell
25,399
-2,035
-7% -$9.59K ﹤0.01% 2945
2024
Q4 		$153K Sell
27,434
-1,104
-4% -$8.66K ﹤0.01% 2878
2024
Q3 		$308K Buy
28,538
+14,067
+97% +$233K ﹤0.01% 2311
2024
Q2 		$304K Buy
+14,471
New +$363K ﹤0.01% 2011

Other funds holding FDMT

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Tudor Investment Corp's FDMT Position: Q1 2026 in Review

Tudor Investment Corp sold out of 4D Molecular Therapeutics (FDMT) in Q1 2026, closing a stake of 31,815 shares — an estimated $239K sold.

Tudor Investment Corp first reported a position in FDMT in Q2 2024 and held it in 7 quarters. The position peaked at $308K in Q3 2024. 152 funds tracked by Wall St. Rank hold FDMT as of Q1 2026.

  • Tudor Investment Corp reported no remaining 4D Molecular Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Tudor Investment Corp sold 31,815 4D Molecular Therapeutics shares in Q1 2026, an estimated $239K.
  • Tudor Investment Corp first reported a position in 4D Molecular Therapeutics in Q2 2024 and held it in 7 quarters.
  • Tudor Investment Corp's 4D Molecular Therapeutics position peaked at $308K in Q3 2024.
  • 152 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q1 2026.

Based on Tudor Investment Corp's 13F filing for Q1 2026, filed 15 May 2026.